HC Wainwright upgraded Collegium Pharmaceutical's rating to "Buy" with a $47.00 price target.
HC Wainwright upgraded Collegium Pharmaceutical's rating to "Buy" and set a $47.00 price target, while other analysts have recently issued varied opinions on the company. Needham & Company LLC reaffirmed its "Hold" rating, Piper Sandler cut the rating to "Neutral", and Jefferies Financial Group upgraded shares from "Hold" to "Buy" and increased the price target. The average rating of Collegium Pharmaceutical is "Moderate Buy" with a consensus target price of $42.00.
August 03, 2024
3 Articles